Status:
COMPLETED
The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Pfizer
Conditions:
Hyperlipidemia
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
Inflammation is important in the both pathogenesis and outcome of atherosclerosis. Plaques containing numerous inflammatory cells, particular macrophages, have a high risk of rupture.We hypothesize th...
Detailed Description
Cardiovascular events are the leading cause of death in developed countries worldwide, including Taiwan. The disruption of atherosclerotic plaques and the subsequent formation of thrombi are currently...
Eligibility Criteria
Inclusion
- Untreated dyslipidemic (LDL cholesterol \>110 mg/dl) subjects with documented atherosclerosis in at least 1 vascular territory: at least moderate (≧4.0mm) aortic atherosclerosis by transesophageal echocardiography or CT/MRI, angiographically documented with coronary artery stenosis (≧50% luminal stenosis), ultrasonographically documented significant extracranial arterial stenosis (≧50%), history of ischemic stroke and transient ischemic attack (TIA), or documented peripheral vascular disease.
Exclusion
- Acute illness,infection, inflammation or major systemic diseases, T-Bil \>3 mg/dl, or Creatinine \>3 mg/dl.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00172419
Start Date
March 1 2007
End Date
December 1 2008
Last Update
January 5 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 10012